November 28, 2023
3 min watch
Save
VIDEO: Novel bispecific antibody shows potential in kidney cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
MADRID — MEDI5752, a novel bispecific antibody binding to CTLA-4 and PD-1, showed potential as a first-line treatment in patients with advanced clear cell renal cell carcinoma, according to data presented at ESMO Congress.
“Although it’s not going to change practice today, it has implications for the future of renal cell carcinoma therapy,” Moshe Ornstein, MD, genitourinary medical oncologist at Cleveland Clinic, told Healio in a video interview.
MEDI5752 (AstraZeneca) is “not quite ready for prime time,” but should be further investigated as a monotherapy as well as in combination with other therapies, according to Ornstein.
Reference:
- Voss MH, et al. Abstract 1883MO. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Ornstein reports consulting honoraria from Merck, and funding to his institution from AstraZeneca and Merck.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.